Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant ...

MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential

MeiraGTx Holdings plc stock surges after a major Eli Lilly partnership boosts funding and pipeline. Click for my updated look ...

Eli Lilly in pact with MeiraGTx to develop gene therapies for eye diseases

MeiraGTx (MGTX) stock climbs as the company partners with Eli Lilly (LLY) to develop and sell gene therapies for eye diseases ...

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive ...

MeiraGTx Shares Rise Premarket on Ophthalmology Collaboration With Eli Lilly

MeiraGTx Holdings shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines said it formed a ophthalmology collaboration potentially worth hundreds of millions of ...
The Bakersfield Californian

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in ...